By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
At RESI JPM 2026, NAUGEN will host the NAUGEN Global Innovation Showcase, a curated session spotlighting four innovative South Korea–based life science companies seeking global expansion through investment and strategic partnerships.
NAUGEN is a global innovation accelerator focused on advancing Novel, Advanced, and Unprecedented technologies across life sciences and deep tech. Through its incubation and acceleration platform, NAUGEN supports founders in scaling high-potential innovations by combining strategic and business development expertise with deep scientific and technological insight. NAUGEN is dedicated to identifying and cultivating breakthrough technologies that remain undiscovered by global markets and accelerating their path toward global competitiveness.
In partnership with George Mason University, NAUGEN recently launched the Northern Virginia International Soft Landing Accelerator (NISA). NISA is designed to help international startups establish and grow their presence in the United States by providing access to investor and partner networks, market-entry support, and lab and office space within Northern Virginia’s rapidly growing innovation ecosystem. Through NISA, global founders receive strategic mentoring, warm introductions to U.S. capital and corporate partners, and a clear pathway to scaling their businesses in the U.S. market.
As part of RESI JPM 2026, the NAUGEN Global Innovation Showcase will feature four companies representing a diverse range of therapeutic, regenerative, and medical-device innovations.
Session Details
NAUGEN Global Innovation Showcase
Date & Time: Monday, January 12, 2026 | 1:00–1:50 pm PST
Location: Golden Gate B, Marriott Marquis San Francisco
All investors and strategic partners interested in learning more about emerging life science innovations with global market potential are welcome to attend.
| RSVP to NAUGEN Global Innovation Showcase |
Participating Companies:
NexThera (https://nexthera.org)
NexThera is a privately held, clinical-stage biotech company developing next-generation treatments for eye diseases and cancer. Its lead program, NT-101, is a first-in-class topical eye-drop therapy for wet age-related macular degeneration (AMD) and has shown encouraging safety and early clinical signals in a U.S. Phase 1/2 study. NT-101 uses a proprietary formulation that allows the medication to remain on the eye surface longer and reach the back of the eye effectively, offering a potential non-injection alternative for patients who currently rely on intravitreal treatments.
Karis Bio (https://karisbio.com)
Karis Bio is a clinical-stage biotech company developing a first-in-class hiPSC-derived endothelial cell therapy to promote new blood vessel formation for ischemic cardiovascular diseases. The company has established a non-viral, non-integrating reprogramming and xeno-free differentiation platform that produces highly pure (>99%) endothelial cells with long-term safety. Its lead assets target severe peripheral artery disease (PAD) and coronary artery disease (CAD), where preclinical studies have demonstrated robust vascular regeneration and improved tissue perfusion.
MedicosBiotech (https://www.medicosbiotech.com)
MedicosBiotech is a regenerative biomaterials company developing spider silk protein–based wound care solutions. The company has achieved the world’s first scalable production of full-length spider silk protein using E. coli, enabling high-purity and cost-efficient manufacturing. Its lead product, CureSilk, has demonstrated superior healing in chronic wound models, including diabetic foot ulcers and pressure ulcers, outperforming FDA-approved comparators in preclinical studies. MedicosBiotech is expanding its platform toward broader applications in regenerative medicine.
ShoeallS (https://shoealls.com/en)
ShoeallS is a technology-driven company developing functional and smart medical footwear powered by its proprietary magnetic vibration module, which has been shown to enhance blood circulation and help alleviate pain. Building on its certified medical-device platform, ShoeallS is advancing next-generation smart shoes that integrate self-powering modules, embedded sensors, and AI-based monitoring to enable real-time patient-health insights. The company is expanding from functional footwear into a broader smart healthcare solution.
Next Phase Newsletter 